# COVER

# Medicine's psychedelic renaissance

For 50 years, virtually all medical research into psychedelic substances stopped. That research has now been renewed—and these radical therapies are again threatening to upend accepted clinical wisdom

> **BY TRISTAN BRONCA** Vancouver

Dr. Gabor Maté with arrest for conducting what it believed to be an unauthorized clinical trial of the hallucinogenic tea called ayahuasca.

Fresh off the success of *In the Realm of Hungry* Ghosts, his book on addiction, Dr. Maté had begun receiving notes about how the brew, which is typically made from the South American *Banisteriopsis* caapi vine and the Psychotria viridis leaf, might be used to treat addiction. At first, he didn't pay much attention, but as the feedback continued to pour in, he soon received an invitation to take part in an ayahuasca ceremony in Vancouver. Dr. Maté—who had spent 12 years of his career treating addicts in the city's Downtown Eastside—accepted.

"I saw immediately why it had potential," he said. "If you told me 10 years ago there's a substance that can do what I've seen it do since, I would have said you're crazy."

Dr. Maté has staked much of his reputation as an addiction physician on a controversial hypothesis: that trauma is at the root of addiction. He theorized that ayahuasca works by breaking down the barrier between the unconscious and conscious parts of the psyche, allowing, among other things, patients to "revisit a childhood experience with the insight of an adult." The idea is that afterward, patients emerge with a clearer understanding of the nebulous pain driving their addiction and are better equipped to escape it. Dr. Maté compared it to forms of meditation or a deep-insight-oriented psychotherapy. "But (those methods) take much longer," he said. "When I do a retreat with ayahuasca, people say it's 10 years of psychotherapy in seven days." It has almost nothing to do with the brew and everything to do with the experience.

This holistic approach has shown promise. In a review of 28 human studies recently published in the *Journal of Psychopharmacology*, the researchers concluded that not only did the ayahuasca experience show "anti-depressive and anti-addictive potentials," it also had a physiological effect on the brain, affecting the size and thickness of the areas

associated with impulse control, decision-making, pain and memory.

When Dr. Maté accepted an invitation to oversee a series of ayahuasca ceremonies at a First Nations community in B.C. (a group suffering from a long history of addiction), he had already been conducting psychotherapeutic work around these ceremonies for a few years. This time, however, a group of researchers from the University of British Columbia had asked to conduct an observational study. Dr. Maté obliged, and shortly after, Health Canada intervened.

"I haven't worked with it in Canada since the warning," Dr. Maté said. While Health Canada has acknowledged—publicly and in writing—that the brew is neither harmful nor addictive, it's still a banned substance, listed in the schedule of Food and Drug Regulations alongside drugs "that are considered to have no medical benefit." That list includes a number of other psychedelics that are now of particular interest to researchers.

But Dr. Maté isn't one of them. He continues to work with the brew in other parts of the world, convinced that its therapeutic potential is too powerful to be ignored, but isn't interested in trying to prove it to his medical colleagues. "I'm 72 years old," he said. "If I waited for all the research to be done and for the stuff to be officially accepted I'd be mouldering in my grave."

# Buried history

Ayahuasca is one of the latest substances to emerge from a blind spot in modern medical research that has spanned nearly 50 years. It is also among a group of age-old hallucinogens that have been used in indigenous healing rituals in the Mojave Desert (peyote), the Amazon basin (ayahuasca) and the jungles of Africa (iboga) for hundreds of years. Perhaps longer. In a podcast for *Vancouver Real*, Mark Haden, chair of the board of directors for the Multidisciplinary Association for Psychedelic Studies (MAPS) Canada, said psychedelics even appear in ancient texts of Greece and India. But up until the last five years or so, they were only seriously studied for about a decade in the 1950s and '60s.

## What happened to LSD?

A partial history of the far-too-popular psychedelic

- Nov. 16, 1938 - Swiss chemist Albert Hofmann synthesizes lysergic acid diethylamide in his lab.
- April 19, 1943 Hofmann accidentally discovers the

psychedelic properties of LSD after he absorbs a small amount through his fingertips.

- 1951 Psychiatrist Dr. Humphry Osmond moves to Weyburn, Sask., to begin his studies on the drug.
- 1953 Project MKUltra, the CIA-sponsored initiative that would become popularly known as "the mind control

studies," begins several ethically dubious experiments with LSD.


• 1957 - Dr. Osmond proposes the term "psychedelic" at a meet-

ing of the New York Academy of Sciences. As he wrote in a letter to author Aldous Hux-



ley: "To fathom Hell or soar angelic, just take a pinch of psychedelic."

• 1957 - AI Hubbard, a former military man and LSD enthusiast, opens a private



can cover the \$500 fee. Celebrities such as Cary Grant soon come seeking their services.

• 1959 – Hubbard leaves the

- clinic for California, where he begins distributing the drug for free to recreational users.
- 1950 to 1965 An estimated 40,000 patients worldwide are treated with LSD.
- 1966 Former Harvard professor Dr. Timothy Leary (PhD), LSD's great popular-

izer, coins the phrase "turn on, tune in, drop out," which would be the high-water



There are myriad reasons for this, but perhaps the most obvious is political. Quite simply, the public views psychedelics very suspiciously, and those views have reverberated through the scientific community. Researchers have been unwilling to risk their reputation studying them and when they did, governments often presented a barrage of logistical and regulatory obstacles that made things prohibitively expensive.

For example, in the MAPS Canada trial for MDMA (ecstasy), the only psychedelic to be studied in Can-

ada in the last 50 years, the drug needed to be kept in what Haden half-jokingly described as a "bomb-proof safe," which required the team to make serious structural changes to the upper floor of a pharmacy. The safe held only about \$2,000 worth of the drug, but the cost of storage was significantly higher.

At the root of this regulatory resistance is one substance: lysergic acid diethylamide, or LSD. Shortly after its psychedelic properties were discovered, LSD almost immediately became a sensation in medical

research communities around the western world. Between 1950 and 1965, the drug was the subject of more than 1,000 scientific papers, dozens of books and six international conferences.

The problem was that it became of great interest to many others as well.

In the early 1950s, the Prairie town of Weyburn, Sask., became the home of one of the world's leading LSD research centres. It was here that psychiatrist Dr. Humphry Osmond showed it could be used to treat personality disorders and alcoholism (the founder of the famous 12-step program was said to have been inspired by an LSD trip). But farther east, at the Allan Memorial Institute in Montreal, the drug was secretly being used for more malicious purposes. In the CIA-backed MKUltra studies, some patients were unwittingly dosed in an effort to develop new interrogation techniques.


Others thought the drugs were far too important to be left in the realm of medicine alone and so began distributing them to musicians, artists and celebrities. Soon, LSD became

a fixture in the American counterculture. The media caught wind of some alarming stories of drug abuse, public opinion (which had been largely positive to that point) did a half-gainer, and by 1970, the drug was banned all over the U.S. and Canada. Meanwhile, LSD vanished quietly from medical school curricula, and new research into psychedelics stopped entirely. Today, few medical students are aware that psychedelics had any history at all in western medicine.

In an interview with continued on ● page 20

mark of the drug's role in the counterculture. Concerns over its dangers also reach a fever pitch.

- May 30, 1966 Governors of Nevada and California sign bills outlawing the drug.
- Oct. 24, 1968 The drug is banned in every U.S. state.
- 1969 Canada outlaws LSD.



Results from some recent clinical studies of psychedelic drugs ▶

# MDMA for PTSD10 of 12 patients

on the drug no longer met the DSM-IV criteria for PTSD after treatment, compared with just two of eight following placeboaided therapy—Journal of Psychopharmacology, Jul. 19, 2010



 Psilocybin for anxiety in advanced-stage cancer patients



Patients dropped 15 points on the STAI anxiety scale and results were still evident six months after just one dose —Archives of General Psychiatry, Sept. 6, 2010

#### Ibogaine for addiction

61% of participants abstinent after treatment but length of time varied. Those who were treated only once remained abstinent for a median of 5.5 months, while those treated multiple times were abstinent for a median of 8.4 months—Journal of Psychopharmacology, Sept. 29, 2014

### Ayahuasca for depression

**Depressive scores dropped** by as much
as **82%** and effects
persisted when measured **21 days** after the
drug was administered
—Revista Brasileira
de Psiquiatria, 2015



hove right: Robert Carter: Jower Jeft: CP Archive: Jower right: iStocknh

**20** NOVEMBER 22, 2016 THE MEDICAL POST | COVER CanadianHealthcareNetwork.ca

#### from • page 19

the CBC, Dr. David Nutt, a British psychiatrist and former drug safety adviser to the U.K. government, said the research chill that occurred since LSD was criminalized amounts to the worst censorship in the history of science.

"It's even worse than when the Catholic Church found a telescope in 1616," he said. "In those days there weren't very many scientists and science wasn't progressing very fast, but in the last 50 years, brain science has increased 10-fold."

# The end

The idea that psychedelic users exposed to (and taken) the drug to come to a clearer understand-

of use had changed. It wasn't until Rick Doblin founded of serious scientific research were rekindled.

MAPS Canada chair Mark Haden first became interested in psychedelics about 10 years ago as a social worker in Vancouver Coastal Health's addiction services. That was where he was exposed to ibogaine, a psychoactive substance found opioids such as heroin or oxycodone. Haden said the only time he's ever heard a patient say they had been healed was after that patient was treated with ibogaine.

Thus began Haden's mission to legitimize research into the drug. He began inviting physicians and other health-care providers to bimonthly dinners in hopes of sparking new discussions. But he had a difficult time getting them on board.

ago," he said, "and when I retired it's interesting how the world changed. Last year, Vancouver Coastal Health invited exact same ideas and I got a completely different reception."

Haden credits the shift in Vancouver to Dr. Evan Wood, an internationally recognized authority on inner-city medicine and medical director of addiction services at Vancouver Coastal Health. He began talking openly about doing psychedelic research and even the possibility of starting a centre dedicated to this research at St. Paul's Hospital. (Interestingly, Dr. Wood credits the shift to new research out of Johns Hopkins University that showed certain psychedelics could help people quit smoking. "It's helped open up people's minds to the need

for novel and safe approaches,"

he wrote in an email.)

After that, attendance at Haden's bimonthly dinners shot up. As he put it, the endorsement gave a lot of people permission.

### Fathom hell or soar angelic

There is an entire Wikipedia page devoted to the urban myths used to warn against the mind-melting dangers of drugs. There's the classic tale of the man who took LSD and believed he could fly, only to

jump from a balcony (or cliff or window) and plummet to his death. Or there's the myth about a group of kids who apparently got so high that they went blind staring at the sun in the middle of the day (it's no coincidence that LSD and marijuana, two of

the most heavily politicized drugs in recent history, factor most heavily in these myths). Perhaps the most lurid tale is



**Mark Haden** 

the bassinet. Most of these stories were hoaxes, while others, like the flying man, overstated the role the drug played (the

original cases usu-

that of the hippie

babysitter who, while

on LSD, put a baby

in the oven and an

uncooked turkey in

ally were ruled to be suicides or more modest cases of misjudgment). Still, their popularity spoke to some very powerful

ADVERTISEMENT NOVEMBER 2016

# of the blackout

are predominantly rock stars, artists and aimless youth is really a holdover from Nixonera thinking. According to Jay Stevens, the author of *Storming* Heaven: LSD and the American *Dream*, the majority of users in the early years of the ban were actually medical researchers and academics who had been in their work. For example, Dr. Osmond's staff—from the nurses to the ward's architects—were asked to take LSD ing of what the patients were experiencing during therapy. It was a sort of chemically aided empathy.

But after the ban, the terms MAPS in 1986 that the flickers


in the African iboga root that is believed to suppress the effects of withdrawal from short-acting

"This was about eight years me back to present to them the


Complete cure 0% clinical involvement of the target toened, and both negative potassium hydrogen examination and lungal culture."

QUESTIONS ANSWER

Mycologic cure was achieved in 55,3% of patients vs.16,8% with vehicle (52 weeks, p.c0.001; secondary endpoint). \*\* Naycologic cure is defined as a negative fungal culture and a negative potessium hydroxide examination of target trenell sample.



Complete cure was achieved in 18.8% of patients vs. 3.5% with vehicle (52 weeks, p<0.001). \*\* Complete cure is defined as 0% chilipal involvement of target to enail plus mycologic cure.



Representative dirtical photographs of two patients with moderate onychomycodis who were treated with JUELIA<sup>M</sup>.



ABOUT JUBLIA

Efineconazole inhibito fungel lancaterol 14c-demethylese involved in ergorismol biosynthesis. The excumulation of 14c-methyl stancis and subsequent loss of ergostanci in the fungi cell wall may be responsible for the fungistatic and fungiddal activity of


Efineconezole is shown in witho to be

substantially edsorbed to locatin but kereth binding it week.

• Elineconezole's low locatin ellinity is expected to result in increased expected to result in increased expected to fee drug to the neil infection ett.

What we the pharmscake purebution through the s BELLA"?

 Efficiencycle penetrates through nells is wire effer JUBLIA<sup>TM</sup> edministration, suggesting drug penetrations to the site of fungal infection in the neal and the neal bed (though clinical relevance is unknown).



- The penetration of AUSUA\*\* was evaluated in on its after investigation after dely application of radioleballed affinessmessia (10%) to human nells for 28 days at 95.1 µL/on/. After 28 days, the cumulative redipentially in the receptor fluid and in the neil pla on a percent basis of total administs radioactivity, was 0.03% and 0.16% (3.11 mg eq/g), respectively. The flux rate was releasely constant from Days 18 to 28 meen 1.40 µg eq/cm/fdey, suggesting steedy state attainment."
- \* Chical algorithments is unincome.

  † Defined as DNs of brickly involvement of target stated plus reporting to
- Defined as a regarder frequency of any analysis process process from the process of the process
- Delited of #2% chical backerson: of copies mend plan is policied one. "Altron complete" on not be used in the complete one into of



"7UBLIA?" (effreconezole topical solution, 10% w/w) is a triazole entilungal agent for

AUBLIA\* is indicated for the topical treatment of mild to moderate onychomycosis (times ungulari) of teenals without lunuls involvement due to Pithophyton rubran and Pithophyton mentgrophytes in immunocompetent adult

estimated prevalence of onychomycosts in the general population in Ontatio was 6.9% (95% CI 5.8-8.0%), it was thought that the estimated prevalence in all of Canada would be similar in magnitude.<sup>8</sup>

A 1956 study estimated the prevelence of toened orychomycosts in diabetic subjects in Ontario to be 32.3% (95% C) 28.3-36.2%).
 Risk fectors for onychomycosts include

Micus nei treume, three pecis,

smolding, diebetes, psoriests and immunocompromised patients.\*\*

onychomycosis recommend that nell

health care providers.

healthy neil.1

gender, family history, vescular disease,

The British Association of Dermetologists' guidelines for the management of toens if

diseases receive attention and care from

Hear was treatment evaluated for terminal enytheraporesis?

Mycologic cure: Negetive potastum hydroidde

examination of the target trensil sample and a negative fungal culture.\(^1\)
A complete cure may be seen some months after a mycologic cure is achieved. This is

ed to time required for outgrowth of

What are some facts about condomy cods? • A 1998 study demonstrated that the

the treatment of nell fungus.

indication



anxieties surrounding the use of LSD in particular. And while the concerns were overblown, they weren't entirely unwarranted. That's especially true for the class of psychedelics known as entheogens.

The entheogens include LSD, psilocybin (found in magic mushrooms), mescaline (found in peyote), and DMT (the active ingredient in ayahuasca) and are defined by their ability to induce a kind of spiritual experience. By contrast, MDMA belongs to a class of psychedelics known

The way practitioners frame the experience can be an especially powerful force for either healing or harm.

as the empathogens, which are named for their ability to induce feelings of connectedness with others. With the empathogens, perhaps the most notable downside is that their use is often followed by

a short period of depression. However, early research has suggested that this "down" often passes unnoticed in MDMA-assisted therapy. Haden compared it to a small wave in a big ocean: people

notice it when they're taking street drugs because their metaphorical ocean is calm and the next day they wake up and they have to go to work or school; but for those who are suffering from mental health disorders, there is already plenty of turbulence.

The entheogens are a different story. In psychedelic research parlance, they "disorient the ego." And despite the clinical applications of this, it can be terrifying.

In a study out of Johns Hopkins University published earlier this year in the Journal of Psychopharmacology, researchers surveyed nearly 2,000 adults about their "bad trips" on magic mushrooms (a very similar experience to taking LSD). Sixty-two per cent said it was among the 10 most difficult situations of their lives (11% said it was the most difficult).

By some accounts, ayahuasca can be worse, since it is almost always accompanied by intense feelings of sickness and vomiting. In a recent story for the New Yorker, one drinker described an early encounter with the brew as the most painful experience of his life "by a factor of a thousand."

"I felt like I was being torn apart," he told the reporter. He went through hours of grand mal seizures and woke up with rug burns on his face the next day.

What these nasty experiences have in common, however, is that they tend to occur in uncontrolled environments. Both Haden and Dr. Maté emphasized that the patient's mindset and the atmosphere (what they refer to as "the set and setting") of psychedelic therapy are as important as the active ingredient. Whether it's an ayahuasquero overseeing an indigenous ceremony, or a psychiatrist presiding over a psilocybin-aided therapy session, the way practitioners frame the experience can be an especially powerful force for either healing or harm.

In properly controlled settings, negative psychological effects such as psychosis are completely absent, and even in the cases of unregulated use, the physical harms aren't usually connected to the psychedelics themselves. With most other pharmaceuticals you can often harm yourself with about six times the recommended dose, but you would have to take about 1,000 times more to overdose on LSD. (The notable exception here is ibogaine, which can have adverse cardiac effects in certain alcohol and opioid users, and so requires much more careful oversight.) With ayahuasca, the most dangerous experiences usually occur when ill-qualified ayahuasqueros attempt to intensify the experience by cutting the brew with another jungle plant called datura, which induces delirium and was used in some cultures as a poison.

Still, unpleasant experiences do happen in clinical settings, but the positive health outcomes aren't usually affected. The Johns Hopkins study found that 76% of the patients surveyed actually walked away from the bad trip with an improved sense of personal well-being and 46% said they

continued on ● page 22



In addition to demonstrated it with and in who equity involving. Brighthyladic meutedichlylytes and Prichaphyton rubrum, efficachezole has been shown to be eather its after against strains of the following organisms thowaver, the safety and effectiveness of efficiencesols in treating direct infections due to these introorganisms have not been established in dinical steich?

- Cerçdicie elbiceras
- Pichophyton tonsurers Pichophyton verucorum
- inchophyton schoenieini
- Epidermophyton floctown Stopubriopais brevious
- Астиполіцт 400.
- fizsefum app. Cendide perepatose Cendide irrusel
- Candida tropicalis
- Affirogramm const

### Hour is AUBLIA" unbed subtensed?



ge is one drop (or two dross for a dig tremail) per uffected mill once dully.

- Apply topically once delly igneferably at
- Apply one drop to effected toenelly) and evo drops to effected big toenelist.
- No debridement is necesse No need to remove previously applied

applications).

Hour long was JUSLIA" word for in distinct Glob?

In clinical studies, patients were treated with JUBLIA Tor up to 48 weeks. Complete cure may be seen some months after mycological cure is exhibited. This is releted to time required for outgrowth of healthy reft.\*

### COUNSELLING: HOW TO USE JUBLIA™ CORRECTLY

Help your petients use AUSUAT correctly to opdinize treatment outcomes:

 Apply ABBAT to clean day toeneds. Wait for at least 10 minutes after showering, bething, or weshing before applying AUSLIAT.

- Aidd the use of trensit polish, cornetic trensit products, or heiling non-health corporates to nat provided politicists white using NELIA\*\*.
- Clip toenal(s) every four weeks and discard dippings. The uneffected toenal(s) should be clipped before the effected ones. To evoid the postbility of spreading the
- infection, do not share toenal dippers with others. Be sure to deen the toenal dippers iter each use. Daily dipping of the toenals is not required
- is not required.
  If a dose of JUBUA<sup>TH</sup> is missed, apply it as soon as possible. However, if it is almost time for the next dose, sligh the missed dose and resume the normal dosing schedule of once a day. Do not double the doses and never make up for the missed dose.

Hour wres AUSLIA" tolorated? AUSLIA" demonstrated a low indidence of edverse reections.

- Total number of patients who reported a treatment-emergent adverse reaction was 6,1 % ABUAT, 3.5% vehicle.<sup>1</sup>
- The only treatment-emergent edverse mediors reported by ~1 % of patients were application site demetitis (2.0% AUBUA\*\*, 0.2% vehicle) and application site vesicles (1.4% AUBUA\*\*, 0.0% vehicle). The majority of adverse events were mild to moderate.

Safety and afficacy in patients under 18 or over 75 have not been studied. Greater sensitivity of some older Individuals (465) cannot be ruled out.

Hypersensithity to efineconezole or any excipients of JUBLIA<sup>TI</sup> or container component

Relevant warnings and precautions:

 Petents with a history or clinical story of immunosuppression, HIV infection, uncontrolled debets, other toened infection except Cardide, toened infection to the matrix, only letteral toened disease, severe

Concomitant use of other entifungal therapy

Selety and efficery of dely use of JUSUA<sup>TH</sup> for longer than 48 weeks have not been established

For topical use only, and only on toenals and immediately edjacent skin
Flammable – losep every from heat or flame
Sensitivity reaction or severe initiation
Fragment and nursing woman

For more information

Please see Product Monograph on the Health Canada website thttp://webprod5.hc-sc.gc.ca dpd-bdpp/index-eng\_sp) for important information on adverse reactions, drug interactions and dosing which have not been discussed in this piece. Product Monograph is also evaluable by calling 1-800-861-4261.



Demonstrated efficacy in a topical.

### LESTYLE TON

Self-management tips for your patients to help avoid neil fungus infections:

- Wish feet regularly with soop and water, including between the toes.
  Keep nells short.
  Don't tim the skin around the nells or pick at it.
- When sodid that absorb sweet, such as wool and rylon, and change sodid frequently. Weer shoes that help reduce humidity or, when possible, weer open shoes. Avoid weeting old shoes (where fungicen hide), or sprinkle the insides with antifungel

powder.

Avoid going berefoot in public please, such as pools, showers and locker rooms.

Aleke sure neil salors strelles their instruments before each pedicure.

Which hands efter touching an infected neil.

Avoid using neil polish and entificial neils, which can irap moisture.

ternational, Inc. or its affiliates. Japant Canada LI, 2150 St-Elevier Med. West Lavel

References

1. J.BLAT Product Monograph. Coates 2015. 2. Gupe AV. or at Previous Monograph. Coates 2015. 2. Gupe AV. or at Previous de de pidemi dografumus pected onychomycate in pasiente visiting dermaciogistal California. In J. Dermacol 1869-196106. 2015. 2015. 3. Gupe AV. or at Previous and epidemiology of overall experimental in disbets subjects a multicente survey. 8t J. Dermacol 1868-1966: 65 1.

4. Thomas J. et all Toural organization and important global disease burden. J. Chr. Phermacol 1869-1966: 55 16.

R. Scher RC. et all the Epidemiology. Biology, and Participal Gograf Corporation and Sarah Coates filed Supplied Cognitions for the management of organization of Computing California C

22 NOVEMBER 22, 2016 THE MEDICAL POST | COVER Canadian Health care Network. ca

#### from • page 21


would be willing to experience it over again. Even the ayahuasca user from the *New Yorker* story would go on to use the brew regularly, claiming the anger he had held onto since childhood disappeared in the months after his initially horrific experience.

"If somebody has a vision of jaguars and anacondas and jungle plants, that's really beautiful but I don't care," said Dr. Maté of ayahuasca. "If somebody has experiences of terror and agony, I also don't

care. What matters to me is the essence of the experience: What is the plant teaching you?"

### The science problem

Phase II clinical trials using MDMA to treat post-traumatic stress disorder recently wrapped up, and both Haden's group and his American counterparts are now seeking approval for phase III trials. If things continue on their current trajectory, Haden is sure MDMA will be approved for psychotherapeutic use in



Canada within five years.

But there continue to be unique challenges in psychedelic therapy. For example,

double-blind clinical trials

have always been impossible because both researchers and patients very quickly become aware of who has been given a placebo. MAPS has been able to manage this problem through creative study design in the MDMA trials, but it's difficult to say whether something like ayahuasca would be able to meet the strict criteria required by Health Canada.

Even if most entheogens could meet those criteria, it's not clear that pharmaceutical companies could make a business case for investing in them—another massive hurdle for expanding their medicinal use. With the exception of LSD and, in Vancouver at least, ibogaine, the entheogens are consumed in something very close to their natural form, which makes it difficult for any one company to control access to them. Plus, the therapeutic value lies in the experience. If that experience is life-altering, as the literature suggests, it isn't usually necessary for people to take the drug much more than once. There are few repeat customers.

Still, some clinicians are confident that these substances will slowly work their way into mainstream medicine. Although, assuming they overcome the other hurdles, such an introduction would require a change in the way we view these drugs, Western medicine, or both.

In a 2014 paper published in *Current Drug Abuse Reviews,* Dr. Kenneth Tupper (PhD), a public health professor at the University of British Columbia, and Dr. Beatriz Labate (PhD), an anthropologist in Guadalajara, Mexico, argue that scientific and legal establishments are always looking to reduce medicines to their active ingredients in the interests of safety and control. To use a common example, cannabis isn't medicine in the eyes of most doctors, but the active ingredients—cannabidiol and tetrahydrocannabinol—are. Ayahuasca defies this reductionism. Every brew is different, as is each patient experience, and to assume that the psychoactive component can be taken out, bottled and prescribed, presumes ("rather unscientifically," the authors argue) that the ceremonial aspects and the non-psychoactive elements of the brew don't have any therapeutic value (recall the importance of set and setting). But the alternative—physician-ordered attendance at an ayahuasca ceremony, for example—seems incompatible with mainstream medicine.

Nevertheless, as Dr. Tupper and Dr. Labate wrote, the scientific worldview has its own built-in biases. Whether or not physicians recognize this may determine whether psychedelics enter popular use or fade to the fringes of alternative medicine. **MP** 

